Funder
Lembaga Pengelola Dana Pendidikan
Universitair Medisch Centrum Groningen
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by her2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010;28:92.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1979;1987(235):182–91.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14:320–68.
4. McKeage K, Perry CM. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2. Drugs. 2002;62:209–43. https://doi.org/10.2165/00003495-200262010-00008. (cited 23 Jan 2023).
5. Jackisch C, Schoenegg W, Reichert D, Welslau M, Selbach J, Harich H-D, et al. Trastuzumab in advanced breast cancer—a decade of experience in Germany. BMC Cancer. 2014;14:924.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献